

PHARMACY AND THERAPEUTICS COMMITTEE MEDICAID MEETING MINUTES

August 28, 2025

Attendance:

Microsoft Teams Meeting

Gary Bledsoe, Staff/Clinical Pharmacist; Dr. Rick Buzard, Associate Chief Medical Officer; Connie Chan, Staff/Clinical Pharmacist; Dr. Edgar Chou, Jefferson Health; Jerry Crawford, Staff/Clinical Pharmacist; Sophie Cweiber, Pharmacy Student Intern; Dr. Neal Demp, Community Behavior Health; Danielle Dolores, Director of Pharmacy; Dr. George E. Downs, Dean Emeritus and Professor, St. Joseph's University; Sharon Ford, Staff/Clinical Pharmacist; Hailey Fry, Centennial Pharmacy; Paul Goebel, Assistant Director Pharmacy, Jefferson Enterprise; Dr. Merleen Harris-Williams, Medical Director; Yelena Hedrick, Staff/Clinical Pharmacist; Gia Ho, Pharmacy Resident; Jessica (Tran) Hoang-Le, Staff/Clinical Pharmacist; Ruth John, Staff/Clinical Pharmacist; Lawrence Jones, Retired Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Hannah McCaffrey, Manager Pharmacy Regulations & Implementation; Brandi Mahler, Supervisor Pharmacy Technicians; Lisa Murray, Staff/Clinical Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Kateryna Puia, Clinical Programs Pharmacist; Pablo Ramirez, Pharmacy Student Intern; Frances Fernandez Rivera, Pharmacy Student Intern; Julie Samuel, Clinical Programs Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovecus, Staff/Clinical Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Justin Steffan, Staff/Clinical Pharmacist; Brian Swift, Enterprise Vice President/Chief Pharmacy Officer, Jefferson Health; Fallan Vaisberg, Formulary Pharmacist; Jeanine Zubrzycki, Staff/Clinical Pharmacist

Excused:

Dr. Paul Aitken, Medical Director; Dr. Demian Elder, Medical Director; Leah Finken, Clinical Programs Pharmacist; Samantha Jackson, Clinical Pharmacist; Sanjiv Raj, Associate VP Customer Engagement; Sara Sadiq, Staff/Clinical Pharmacist; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health

Minutes taken by: Joana Iverson

I. Administrative Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
Minutes Review/Approval	D. Dolores presented the minutes from the May 2025 meeting to the Committee for review.	The Committee approved the minutes from our last meeting as presented.	D. Dolores	Resolved

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
	<ul style="list-style-type: none"> • <i>Welcome New Resident Gia Ho</i> • <i>DHS P&T scheduled for September 24th and 25th</i> 	<i>Informational</i>	<i>D. Dolores</i>	

II. Drug Formulary Review/Update


TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<i>Non-PDL Prior Authorization Criteria Review</i>	<p><i>The Committee reviewed the Non-PDL Prior Authorization Criteria and approved as presented.</i></p> <ul style="list-style-type: none"> • <i>Benlysta</i> • <i>Early Refill</i> • <i>Gattex</i> • <i>Journavx</i> • <i>Kerendia</i> • <i>Non-Preferred Drug (Non-PDL)</i> • <i>Pulmozyme</i> • <i>Quantity Limits</i> • <i>Radicava Oral Solution</i> • <i>Synagis</i> • <i>Tolvaptan</i> • <i>Xdemvy</i> • <i>Xyrem-Xywav</i> • <i>Zoryve 0.3% Foam</i> • <i>Wegovy – CHIP only</i> 	<i>The Committee approved as presented.</i>	<i>F. Vaisberg</i> <i>C. Chan</i> <i>J. Crawford</i> <i>R. John</i> <i>M. Prokopets</i>	<i>Resolved</i>
<i>Quantity Limit Additions and Updates</i>	<p><i>The Committee reviewed the Quantity Limit Additions. The Committee approved as presented.</i></p> <ul style="list-style-type: none"> • <i>Brynovin 25 mg/mL solution - 4 mL/day</i> • <i>Fanapt Titration Pack B - 2 per day</i> • <i>Fanapt Titration Pack C - 2 per day</i> • <i>Kerendia tablet - 1 per day</i> • <i>Mounjaro pen - 0.08 mL/day</i> • <i>Otulfî 130 mg/26mL vial - 1.86 mL/day</i> • <i>Otulfî 45 mg/0.5mL syringe - 0.02 mL/day</i> • <i>Otulfî 90 mg/mL syringe - 0.04 mL/day</i> • <i>Selarsdi 130 mg/26mL vial - 1.86 mL/day</i> • <i>Selarsdi 45 mg/0.5mL syringe - 0.02 mL/day</i> • <i>Selarsdi 90 mg/mL syringe - 0.04 mL/day</i> • <i>Steqeyma 130 mg/26mL vial - 1.86 mL/day</i> • <i>Steqeyma 45 mg/0.5mL syringe - 0.02 mL/day</i> 	<i>The Committee approved the Quantity Limit Additions as presented. It will be sent to PARP for approval.</i>	<i>F. Vaisberg</i>	<i>Resolved</i>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
	<ul style="list-style-type: none"> • Steqeyma 90 mg/mL syringe - 0.04 mL/day • Ustekinumab-ttwe 130mg/26mL vial - 1.86 mL/day • Ustekinumab-ttwe 45mg/0.5mL syringe - 0.02 mL/day • Ustekinumab-ttwe 90 mg/mL syringe - 0.04 mL/day • Chlorhexidine gluconate 0.12% solution - 31.54 mL/day • Fleet bisacodyl 10 mg/30mL enema- <i>QL removed</i> 			
III. Specialty Drug Additions	<p>The Committee reviewed the Specialty Drug Additions. The Committee approved as presented.</p> <ul style="list-style-type: none"> • Andembry 200mg/1.2mL auto-injector • Anzupgo 2% cream • Avmapki Fakzynja Co-pack • Bonsity 560mg/2.24mL injection • Ekterly 300mg tablet • Ibtrozi 200mg capsule • Lynozyfic 5mg/2.5mL, 200mg/10mL injection • Nilotinib 50mg, 150mg, 200mg capsules • Pychiva 90mg/mL injection • Sephience 250mg, 1000mg powder • Tolvaptan 15mg, 30mg tablets and blister packs • Yeztugo 300mg tablet • Yeztugo 463.5mg/1.5mL subcutaneous solution • Yutrepia inhalation powder, for oral inhalation • Zevaskyn gene-modified cellular sheets 	The Committee approved as presented. The Specialty Drug Additions will be sent to PARP for approval.	F. Vaisberg	Resolved
IV. New Drug Review	<p>G. Ho presented the New Drug Review list to the Committee. The following new products were reviewed and will be kept as non-formulary:</p> <ul style="list-style-type: none"> • Anzupgo (delgocitinib) Topical Cream • Kirsty (insulin aspart-xjhz) Injection • Ekterly (sebetralstat) Tablets • Zegfrovy (sunvozertinib) Tablets • Lynozyfic (linvoseltamab-gcpt) Injection • Harliku (nitisinone) Tablets • Yeztugo (lenacapavir) Tablets and Injections • Andembry (garadacimab-gxii) Injection • Arynta (lisdexamfetamine dimesylate) Oral Solution • Zusduri (mitomycin) for Intravesical Solution, formerly UGN-102 • Ibtrozi (taletrectinib) Capsules • Enflonsia (clesroyimab-cfor) Injection • Widaplik (amlodipine, indapamide and telmisartan) Tablets 	The Committee approved the New Drug Review as presented and recommended.	G. Ho	Resolved

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
	<ul style="list-style-type: none"> • <i>Xifyrm (meloxicam) Injection</i> • <i>MNEXSPIKE (Covid-19 Vaccine, mRNA) Injection</i> • <i>Tryptyr (aolctremon) Ophthalmic Solution</i> • <i>Khindivi (hydrocortisone) Oral Solution</i> • <i>Yutrepia (treprostinil) Inhalation Powder</i> • <i>Starjemza (usetekinumab-hmny) Injection</i> • <i>Nuvaxovid (Covid-19 Vaccine, Adjuvanted) Injectable Suspension</i> • <i>Brekiya (dihydroergotamine mesylate) Injection</i> • <i>Emrelis (telisotuzumab vedotin-tilv) Lyophilized Powder for Injection</i> • <i>Avmapki Fakzynja Co-Pack (avutometinib and defactinib, co-packaged) Capsules/Tablets</i> • <i>Atzumi (dihydroergotamine mesylate) Nasal Powder</i> • <i>Imaavy (nipocalimab-aahu) Injection</i> • <i>Zevaskyn (prademagene zamikeracel) Gene-Modified Cellular Sheets</i> • <i>Mezofy (aripiprazole) Oral Film</i> • <i>HemiClor (chlorthalidone) Tablets</i> 			

V. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held October 2025.



9/5/2025

Danielle Dolores, Director of Pharmacy Services

Date